WALTHAM, Mass., Oct. 1, 2015 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Company Management will be participating in four upcoming conferences.
- 18th Annual Cowen and Company Therapeutics Conference – New York, NY (October 5-6, 2015) Adam Gridley, Histogenics’ CEO, will be participating in the event with investors and clinical experts, which will review key trends and developments in the most important therapeutic areas of the $500+ billion global drug market.
- Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa – La Jolla, CA (October 7-9, 2015) Adam Gridley, Histogenics’ CEO, will be presenting a corporate overview as part of the Meeting’s Partnering Forum on Thursday, October 8, 2015, at 1:30 pm PDT. Co-hosted by the Alliance for Regenerative Medicine, the California Institute for Regenerative Medicine, and the Sanford Consortium for Regenerative Medicine, the 2015 Stem Cell Meeting on the Mesa is a three-day conference featuring the program’s two-day Partnering Forum, the Public Forum lecture, and a full-day scientific symposium.
- 14th Annual BIO Investor Forum – San Francisco, CA (October 20-21, 2015) Adam Gridley, Histogenics’ CEO, will be presenting a corporate overview on Tuesday, October 20, 2015. The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The conference will explore trends and opportunities in life sciences, with a focus on venture-stage growth and emerging public companies as well as those poised to join the growth “watch list” in 2015.
- Sofinnova Japan Biopharma Partnering Conference – Tokyo, Japan (October 27, 2015)Adam Gridley, Histogenics’ CEO, will be presenting a corporate overview on Tuesday, October 27, 2015. The Sofinnova Japan Biopharma Partnering Conference brings together premier biotechnology companies from North America and Europe with influential Japanese licensing and business development executives.
The presentations that are webcast live may be accessed by visiting the Investor Relations section of Histogenics’ website at www.histogenics.com. The webcasts will be available on Histogenics’ website for approximately 45 days following the respective conferences.
About Histogenics Corporation
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Histogenics’ first investigational product candidate, NeoCart®, leverages its platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee.
